Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Novartis

Status and phase: Completed; Phase 2

Conditions: Pandemic H5N1 Influenza

Treatments: Biological: Adjuvanted H5N1 pandemic influenza vaccine

Study type: Interventional

Funder types: Industry; Other U.S. Federal agency

Identifiers

NCT01766921

V89_13

Details and patient eligibility

About

Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects

Enrollment: 1,393 patients

Sex: All

Ages: 65+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy elderly subjects ≥65 years,
2. Individuals willing to provide written informed consent,
3. Individuals in good health,
4. Individuals willing to allow for their serum samples to be stored beyond the study period.

Exclusion criteria

1. Individuals not able to understand and follow study procedures,
2. History of any significant illness,
3. History of any serious chronic medical condition or progressive disease,
4. Presence of medically significant cancer,
5. Known or suspected impairment/alteration of immune function,
6. Presence of any progressive or severe neurologic disorder,
7. Presence of any bleeding disorders or conditions that prolongs bleeding time,
8. History of allergy to vaccine components,
9. Receipt of any other investigational product within 30 days prior to entry into the study,
10. History of previous H5N1 vaccination,
11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,
12. Receipt of any other vaccine within 2 weeks prior to entry into the study
13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,
14. Body mass index (BMI) ≥ 35 kg/m2,
15. History of drug or alcohol abuse,
16. Any planned surgery during study period,
17. Individuals conducting the study and their immediate family members,
18. Individuals with behavioral or cognitive impairment or psychiatric diseases.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,393 participants in 2 patient groups

aH5N1c - High dose

Experimental group

Treatment:

Biological: Adjuvanted H5N1 pandemic influenza vaccine

aH5N1c - Low dose

Experimental group

Treatment:

Biological: Adjuvanted H5N1 pandemic influenza vaccine